Curis, Inc. (CRIS)
| Previous close | 15.99 |
| Open | 16.74 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 16.05 - 16.99 |
| 52-week range | 0.38 - 17.49 |
| Volume | |
| Avg. volume | 29,803 |
| Market cap | 97.546M |
| Beta (5Y monthly) | 3.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET.
- PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2024, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 8,550 shares of Curis common stock to a new employee, with a grant date of April 1, 2024 (the "Q2 2024 Inducement Grant").
- PR Newswire
Curis to Present at Upcoming Healthcare Conferences in April
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the 23rd Annual Needham Virtual Healthcare Conference being held on April 8 - 11, 2024. Presentation details are as follows:
